Yun Zhong
Stock Analyst at Wedbush
(0.68)
# 3,734
Out of 4,786 analysts
28
Total ratings
36%
Success rate
-16.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $70 | $48.24 | +45.11% | 2 | Mar 28, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Outperform | n/a | $3.36 | - | 1 | Mar 12, 2025 | |
| PASG Passage Bio | Assumes: Outperform | $4 | $0.37 | +979.04% | 2 | Nov 29, 2024 | |
| MLTX MoonLake Immunotherapeutics | Assumes: Outperform | $92 → $73 | $37.87 | +92.76% | 1 | Nov 5, 2024 | |
| RZLT Rezolute | Initiates: Outperform | $12 | $2.80 | +328.57% | 1 | Nov 5, 2024 | |
| AVXL Anavex Life Sciences | Maintains: Buy | $35 → $28 | $8.29 | +237.76% | 2 | Feb 9, 2023 | |
| TSHA Taysha Gene Therapies | Downgrades: Neutral | n/a | $1.25 | - | 2 | Feb 2, 2023 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $14 → $16 | $8.08 | +98.14% | 1 | Jan 18, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $125 → $160 | $65.03 | +146.03% | 11 | Dec 22, 2022 | |
| RCKT Rocket Pharmaceuticals | Initiates: Buy | $35 | $6.42 | +445.60% | 1 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $700 | $4.97 | +13,998.69% | 2 | Jul 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $10.27 | +347.91% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.21 | +353.51% | 1 | May 5, 2021 |
Protagonist Therapeutics
Mar 28, 2025
Reiterates: Outperform
Price Target: $70
Current: $48.24
Upside: +45.11%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Outperform
Price Target: n/a
Current: $3.36
Upside: -
Passage Bio
Nov 29, 2024
Assumes: Outperform
Price Target: $4
Current: $0.37
Upside: +979.04%
MoonLake Immunotherapeutics
Nov 5, 2024
Assumes: Outperform
Price Target: $92 → $73
Current: $37.87
Upside: +92.76%
Rezolute
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $2.80
Upside: +328.57%
Anavex Life Sciences
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $8.29
Upside: +237.76%
Taysha Gene Therapies
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.25
Upside: -
Amicus Therapeutics
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $8.08
Upside: +98.14%
Sarepta Therapeutics
Dec 22, 2022
Maintains: Buy
Price Target: $125 → $160
Current: $65.03
Upside: +146.03%
Rocket Pharmaceuticals
Nov 1, 2022
Initiates: Buy
Price Target: $35
Current: $6.42
Upside: +445.60%
Jul 1, 2021
Downgrades: Hold
Price Target: $700
Current: $4.97
Upside: +13,998.69%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $10.27
Upside: +347.91%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $2.21
Upside: +353.51%